Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Haoran Xia(Tongji University), Gening Jiang(Tongji University), Wenxin He(Tongji University), Xiaomiao Zhang(Shanghai Jiao Tong University), Hezhong Chen(Tongji University), Deping Zhao(Second Military Medical University), Dongliang Bian(Tongji University), Nan Song(Tongji University), Xinsheng Zhu(Tongji University), Liang Duan(Dalian Medical University), Huibiao Zhang(Tongji University), Zheng Ruan(Key Laboratory of Guangdong Province), Jian Chen(University of Science and Technology of China), Peng Zhang(Shenyang Pharmaceutical University), Xiaogang Liu(Tongji University), Han Zhang(Guangzhou University of Chinese Medicine), Jing Zhang(Shanghai Jiao Tong University), Haiping Zhang(Tongji University), Lele Zhang(Tongji University), Yongxin Zhou(Tongji University), Shiliang Xie(Tongji University), Liangdong Sun(Tongji University), Huansha Yu(Shanghai Pulmonary Hospital), Jie Yang(Tongji University), Fenghuan Sun(Tongji University), Dongfang Tang(Hunan Normal University), Yuming Zhu(Third People 's Hospital of Chongqing), Qinchuan Li(Shanghai East Hospital), Guohan Chen(Shanghai East Hospital)
Signal Transduction and Targeted Therapy
June 13, 2024
Cited by 30


Related Papers